Baidu
map

Cancer Prev Res:二甲双胍可能还能降低糖尿病患者的肺癌风险

2015-02-03 MedSci MedSci原创

最新研究指出,对于不吸烟的糖尿病患者,降糖药二甲双胍的作用不仅能够控制血糖,还能降低肺癌的患病率。研究结果发表在最新一期美国癌症研究协会旗下的Cancer Prevention Research杂志上。该项研究由加利福尼亚洲奥克兰市Kaiser Permanente研究部科学家Lori Sakoda博士主持。“一些实验室研究和观察性研究提示,二甲双胍可能具有预防癌症的作用。然而,” Lori Sa

最新研究指出,对于不吸烟的糖尿病患者,降糖药二甲双胍的作用不仅能够控制血糖,还能降低肺癌的患病率。研究结果发表在最新一期美国癌症研究协会旗下的Cancer Prevention Research杂志上。该项研究由加利福尼亚洲奥克兰市Kaiser Permanente研究部科学家Lori Sakoda博士主持。“一些实验室研究和观察性研究提示,二甲双胍可能具有预防癌症的作用。然而,” Lori Sakoda博士指出,“从人类身上研究的数据来看,这却是相互矛盾的。因此,研究人员进行了这项研究,进一步阐明使用二甲双胍和肺癌发病风险之间的联系。”Sakoda和他的同事对47351名糖尿病患者(其中男性占54% )进行了一项回顾性队列研究。该群患者年龄为40岁或以上,均在1994年和1996年之间完成了健康相关信息调查。他们的糖尿病药物使用记录被药房的电子记录所收集。记录中在六个月期间使用两个或两个以上的二甲双胍处方的患者,被定义为二甲双胍“终身使用者”,约占总人数的46%。在15年的随访中,总共有747名患者被诊断出患有肺癌,其中80名为不吸烟者,而203名当时是吸烟者。研究结果发现,二甲双胍

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-11-10 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-22 orthoW

    不错的文章,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-17 chinayinhan

    已阅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-05 lovetcm

    评价比较客观

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-04 61.148.243.**

    神奇的都是经典

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2045551, encodeId=382e204555115, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Feb 05 06:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061454, encodeId=56d22061454a0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Nov 10 17:00:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16702, encodeId=d80716e0274, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:22:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16265, encodeId=98e41626584, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:06:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473852, encodeId=494614e385229, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Feb 05 12:00:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15076, encodeId=11c5150e656, content=评价比较客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 00:04:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15050, encodeId=202c15050a7, content=神奇的都是经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.148.243.**, createdTime=Wed Feb 04 11:05:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15033, encodeId=8c8f15033e1, content=二甲双胍马上要和阿司匹林一样神奇了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160701/IMG57766D0F679469828.jpg, createdBy=d47d28603, createdName=200750383, createdTime=Tue Feb 03 23:57:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-03 200750383

    二甲双胍马上要和阿司匹林一样神奇了?

    0

相关资讯

JCEM:二甲双胍用于2型糖尿病一线治疗优于阿卡波糖

心血管疾病是2型糖尿病患者常见并发症之一,也是导致患者死亡的主要原因。既往的研究已证实,作为一线降糖药物,二甲双胍在降低血糖的同时还能有效减少心血管并发症的发生。 近期的研究显示,阿卡波糖在降低血糖和减少心血管并发症方面或与二甲双胍的疗效相当。因此,有指南推荐阿卡波糖可作为一线降糖治疗的另一治疗选择。 然而,尽管有一些证据支持上述观点,但目前尚缺乏二甲双胍和阿卡波糖直接比较的研

JAMA:二甲双胍在2型糖尿病和肾脏疾病中的应用

普遍认为,二甲双胍是首选的治疗2型糖尿病的口服降糖药物。但是,由于其有导致乳酸酸中毒的风险,一直禁用于合并严重肾脏疾病的糖尿病患者。最近发表在JAMA上一篇文章,系统的评价合并严重肾脏疾病的糖尿病患者使用二甲双胍,出现乳酸酸中毒的风险。文章搜索了MEDLINE和 Cochrane两个数据库中,从1950年到2014年6月,所有关于二甲双胍,肾脏疾病,乳酸酸中毒的英文文献。排除了综述、快报、评论、案

Eur J Cancer:二甲双胍能降低2型糖尿病患者前列腺癌风险

二甲双胍是最常用的口服降糖药,目前已成为公认的“全球控制糖尿病的核心药物”,是“糖尿病治疗中的基石”。除了抗糖尿病作用之外,也有研究报道二甲双胍还可通过一系列不同的机制来阻碍肿瘤的进展和肿瘤的形成。9月发表在Eur J Cancer的一项来自台湾的population base的研究表明,二甲双胍能降低2型糖尿病患者前列腺癌风险。 前列腺癌是男性最常见的恶性

Diabetes Obes Metabo:二甲双胍对肥胖儿童的影响

根据公布在Diabetes, Obesity and Metabolism杂志上一则研究提示,对于肥胖儿童,二甲双胍似乎可以降低饥饿感和增加饱腹感觉。 美国国立卫生研究院Mopelola A. Adeyemo和他的同事对年龄在6至12岁的100名肥胖高胰岛素血症儿童,进行了一项为期6个月的随机、双盲、安慰剂对照试验,以评估二甲双胍对体重和能量平衡的影响,共84名儿童数据可用(45名二甲双胍治

JAMA:二甲双胍对肾病患者安全

2型糖尿病最流行的治疗药物是二甲双胍。根据耶鲁大学研究人员在JAMA杂志上发表的回顾性研究发现,二甲双胍对伴有轻度至中度肾脏疾病的糖尿病患者也可能是安全的。 20年来,在美国二甲双胍已用于降低2型糖尿病患者的血糖。大多数专家认为是治疗2型糖尿病血糖升高最好的药物。尽管其有强大的安全性,但FDA已经长期推荐二甲双胍不被推荐治疗伴有轻度至中度肾脏疾病的糖尿病患者,原因是由于乳酸性酸中毒。但是,这

Diabetes Obes Metab:2型糖尿病一线单药治疗二甲双胍的死亡率低于磺脲类

2型糖尿病患者的治疗,胰岛素的作用效果较差,可以通过某些口服药物刺激体内胰岛素的分泌,二甲双胍和磺脲是两大选择。2014年10月发表在Diabetes Obes Metab.的一项英国研究,对一线单药治疗使用磺脲或二甲双胍患者全因死亡和主要不良心血管事件(MACE)的风险进行了评估,结果发现2型糖尿病患者一线单药治疗磺脲的死亡率高于二甲双胍。 数据来源于临床实践研究数据链(C

Baidu
map
Baidu
map
Baidu
map